Core Insights - Casey's General Stores has seen significant activity from institutional investors, with notable increases in holdings and new positions being established in the second and third quarters of the year [1][7] - The company reported strong quarterly earnings, exceeding consensus estimates, with a year-over-year revenue increase of 14.2% [4] - A quarterly dividend has been announced, reflecting a modest payout ratio and providing a yield of 0.4% [5] Institutional Investor Activity - Nvwm LLC acquired a new position worth approximately $32,000 in Casey's General Stores during the second quarter [1] - Rossby Financial LCC increased its holdings by 580.0%, now owning 68 shares valued at $35,000 after purchasing an additional 58 shares [1] - Bogart Wealth LLC raised its holdings by 388.5% in the third quarter, now owning 127 shares worth $72,000 after acquiring 101 additional shares [1] - Institutional investors collectively own 85.63% of the company's stock [1] Insider Transactions - Director Moats Maria Castanon purchased 300 shares at an average cost of $554.66 per share, increasing their position by 59.64% [2] - Following the transaction, the director owns 803 shares valued at approximately $445,391.98 [2] - Corporate insiders own 0.54% of the stock [2] Stock Performance - The stock opened at $606.50, with a 1-year low of $372.08 and a high of $647.99 [3] - The market capitalization stands at $22.48 billion, with a price-to-earnings ratio of 37.30 and a PEG ratio of 2.16 [3] - The stock's 50-day moving average is $579.60, and the 200-day moving average is $548.48 [3] Earnings Report - The company reported earnings per share (EPS) of $5.53, surpassing the consensus estimate of $4.92 by $0.61 [4] - Revenue for the quarter was $4.51 billion, matching the consensus estimate [4] - The net margin was 3.58%, and return on equity was 16.89% [4] Dividend Announcement - A quarterly dividend of $0.57 per share will be paid on February 13th, with a record date of February 1st [5] - This represents an annualized dividend of $2.28 and a payout ratio of 14.02% [5] Analyst Ratings - Zacks Research upgraded the stock from "hold" to "strong-buy" [6] - KeyCorp set a price target of $680.00, while Bank of America initiated coverage with a "buy" rating [6] - The consensus rating is "Moderate Buy" with a price target of $624.09 [6]

Core Viewpoint - Johnson & Johnson is set to report its fourth-quarter earnings on January 21, with expectations of increased earnings per share and revenue compared to the previous year [1] Financial Performance - Analysts predict fourth-quarter earnings of $2.47 per share, up from $2.04 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $24.16 billion, an increase from $22.52 billion reported last year [1] Recent Developments - On January 14, Johnson & Johnson announced topline results from the Phase 3 MajesTEC-9 study of Tecvayli for multiple myeloma, which may impact investor sentiment [2] - Following the announcement, shares of Johnson & Johnson fell by 0.2% to close at $218.21 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 [4] - Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $197 to $217 [4] - Goldman Sachs analyst Asad Haider maintained a Buy rating and raised the price target from $213 to $240 [4] - B of A Securities analyst Tim Anderson maintained a Neutral rating and increased the price target from $204 to $220 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 [4]

Core Insights - J.B. Hunt Transport Services, Inc. is set to release its fourth-quarter earnings on January 15, with expected earnings of $1.81 per share, an increase from $1.53 per share in the same period last year [1] - The anticipated quarterly revenue for J.B. Hunt is $3.12 billion, slightly down from $3.15 billion a year earlier [1] Dividend and Share Repurchase - On October 22, J.B. Hunt announced a quarterly dividend and a new $1 billion share repurchase authorization [2] - Following this announcement, J.B. Hunt shares experienced a decline of 0.6%, closing at $205.17 [2] Analyst Ratings and Price Targets - Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and raised the price target from $168 to $223 [3] - JP Morgan analyst Brian Ossenbeck maintained an Overweight rating and increased the price target from $176 to $211 [3] - Bernstein analyst David Vernon maintained a Market Perform rating and raised the price target from $158 to $195 [3] - Goldman Sachs analyst Jordan Alliger maintained a Neutral rating and raised the price target from $169 to $187 [3] - Citigroup analyst Ariel Rosa downgraded the stock from Buy to Neutral while raising the price target from $175 to $221 [3]

Core Insights - Franklin Covey Co. is set to release its first-quarter earnings results on January 7, 2025, after market close [1] - Analysts predict earnings of 13 cents per share, a decrease from 20 cents per share in the same quarter last year [1] - The expected quarterly revenue is $64.77 million, down from $69.09 million year-over-year [1] - The company reported mixed results for the fourth quarter on November 5 [1] Stock Performance - Franklin Covey's shares fell by 0.8%, closing at $16.64 on the previous Friday [2] Analyst Ratings - Barrington Research analyst Alexander Paris maintains an Outperform rating with a price target of $22, reflecting an 80% accuracy rate [3] - Roth Capital analyst Jeff Martin has a Buy rating but reduced the price target from $30 to $27, with a 68% accuracy rate [3]

Analyst Upgrades and Downgrades - Goldman Sachs upgraded Teradyne from "sell" to "buy" with a target price increase from $148.00 to $230.00 [1] - UBS raised its price target from $165.00 to $200.00 and maintained a "buy" rating [1] - Bank of America upgraded Teradyne from "underperform" to "buy" with a price objective of $205.00 [1] - Evercore ISI increased its price objective from $120.00 to $175.00 and rated the stock as "outperform" [1] - JPMorgan Chase raised its target price from $122.00 to $190.00 and assigned a "neutral" rating [1] - The consensus rating for Teradyne is "Moderate Buy" with a target price of $185.75 [1] Financial Performance - Teradyne reported $0.85 earnings per share (EPS) for the last quarter, exceeding estimates of $0.78 by $0.07 [3] - The company had revenue of $769.21 million, surpassing analyst estimates of $744.20 million [3] - Quarterly revenue increased by 4.3% year-over-year [3] - The return on equity was 18.04% and the net margin was 15.49% [3] Dividend Announcement - Teradyne announced a quarterly dividend of $0.12 per share, paid on December 17th [4] - The annualized dividend is $0.48, yielding 0.2% [4] - The dividend payout ratio is currently 17.45% [4] Stock Performance - Teradyne's stock reached a new 52-week high of $205.30 during trading [5] - The stock traded at $205.1880 with a volume of 233,326 shares [5] - The company's market capitalization is $32.51 billion, with a P/E ratio of 75.48 [2] Insider Transactions - CEO Gregory Stephen Smith sold 1,108 shares at an average price of $201.31, totaling $223,051.48 [6] - Following the sale, the CEO owns 93,409 shares valued at approximately $18.8 million [6] - Insiders sold 3,324 shares worth $583,639 over the last quarter [6] Institutional Inflows and Outflows - Bank of Nova Scotia increased its holdings in Teradyne by 546.5%, acquiring an additional 83,055 shares [7] - Mirae Asset Global Investments raised its stake by 3.4%, now owning 277,002 shares [7] - Thrivent Financial for Lutherans lifted its position by 291.6%, owning 24,995 shares [7] - Hedge funds and institutional investors own 99.77% of Teradyne's stock [7] Company Overview - Teradyne, Inc. is a global supplier of automatic test equipment and related services for semiconductors and electronic systems [8] - The company was founded in 1960 and is headquartered in North Reading, Massachusetts [8] - Teradyne's product portfolio focuses on automatic test equipment (ATE) and system-level test solutions [9]

Core Viewpoint - Carnival Corporation is expected to report improved earnings and revenue for its fourth quarter, indicating a positive trend in financial performance [1][2]. Financial Performance - The company is projected to report quarterly earnings of 25 cents per share, an increase from 14 cents per share in the same period last year [1]. - The consensus estimate for quarterly revenue is $6.37 billion, compared to $5.94 billion a year earlier [1]. Analyst Ratings - Carnival has exceeded analyst revenue estimates for six consecutive quarters and in nine of the last ten quarters overall [2]. - UBS analyst Robin Farley maintained a Buy rating and raised the price target from $35 to $37 [3]. - Barclays analyst Brandt Montour maintained an Overweight rating and reduced the price target from $37 to $36 [3]. - Susquehanna analyst Christopher Stathoulopoulos maintained a Positive rating and increased the price target from $35 to $40 [3]. - Wells Fargo analyst Trey Bowers maintained an Overweight rating and raised the price target from $34 to $35 [3]. - Citigroup analyst James Hardiman maintained a Buy rating and lowered the price target from $38 to $36 [3].

Group 1 - Top Wall Street analysts have changed their outlook on several major companies, indicating a shift in market sentiment [1] - Analysts have provided insights on CVX stock, suggesting potential investment opportunities [1]

Core Viewpoint - The Lovesac Company is expected to report a significant quarterly loss and a slight increase in revenue compared to the previous year [1] Financial Performance - The company will release its third-quarter earnings results on December 11, with analysts predicting a loss of 46 cents per share, compared to a loss of 1 cent per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $154.17 million, which represents an increase from last year's revenue of $149.91 million [1] Stock Performance - Shares of Lovesac fell by 1.5%, closing at $13.74 [2] Analyst Ratings - Maxim Group analyst Tim Forte maintains a Buy rating with a reduced price target of $33, down from $38 [3] - DA Davidson analyst Michael Baker also maintains a Buy rating with a price target of $24 [3] - Canaccord Genuity analyst Maria Ripps keeps a Buy rating with a price target of $30 [3] - Oppenheimer analyst Brian Nagel has an Outperform rating with a price target of $35 [3] - Roth MKM analyst Matt Koranda maintains a Buy rating and raised the price target from $22 to $28 [3]

Core Insights - Macy's, Inc. is expected to report a quarterly loss of 13 cents per share for Q3, a decline from a profit of 4 cents per share in the same period last year [1] - The consensus estimate for Macy's quarterly revenue is $4.56 billion, down from $4.74 billion a year earlier [1] - The company's board declared a regular quarterly dividend of 18.24 cents per share on October 24 [1] Stock Performance - Shares of Macy's fell 0.5% to close at $22.71 [2] Analyst Ratings - UBS analyst Jay Sole maintained a Sell rating and raised the price target from $6.5 to $7 [4] - Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and increased the price target from $17 to $22 [4] - Citigroup analyst Paul Lejuez maintained a Neutral rating and raised the price target from $16 to $19 [4] - BTIG analyst Robert Drbul initiated coverage with a Neutral rating [4] - Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating and raised the price target from $12 to $16 [4]

Earnings Report - Pfizer Inc. is set to release its third-quarter earnings results on November 4, with analysts expecting earnings of 64 cents per share, a decrease from $1.06 per share in the same period last year [1] - The consensus estimate for Pfizer's quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier [1] Legal Action - Pfizer has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk in a Delaware Court, claiming breach of contract, breach of fiduciary duty, and tortious interference due to Metsera's failure to meet obligations under a merger agreement with Pfizer [2] - Following the lawsuit, Pfizer's shares rose by 0.04% to close at $24.66 [2] Analyst Ratings - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and reduced the price target from $33 to $32 [5] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $28 to $30 [5] - Citigroup analyst Andrew Baum maintained a Neutral rating and increased the price target from $25 to $26 [5] - UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $24 to $25 [5] - Cantor Fitzgerald analyst Carter Gould initiated coverage with a Neutral rating and a price target of $24 [5]